BBMRI-ERIC Podcast

BBMRI-ERIC

A podcast that tells the latest success stories and innovations from across the European biobanking and biomolecular resources landscape.

  1. 34 - Ángel Álvarez-Prado profile: “I think it was game changing in my career. It was just a once in a lifetime experience.”

    18 SEPT

    34 - Ángel Álvarez-Prado profile: “I think it was game changing in my career. It was just a once in a lifetime experience.”

    Meet Dr. Ángel Álvarez-Prado, principal investigator at the Translational Cancer Immunogenomics Lab at the Luxembourg Institute of Health. His journey took him from a curious child and self-described “computer nerd” to the head of his own laboratory, dedicated to advancing cancer treatment. Ángel first crossed paths with BBMRI-ERIC in 2023 while working as a postdoctoral fellow at the Ludwig Institute for Cancer Research at the University of Lausanne. He was selected to participate in the Lindau Nobel Laureate Meeting, an annual event where young scientists have the rare opportunity to engage with Nobel Laureates and explore breakthroughs in their fields. BBMRI-ERIC sponsored Ángel’s participation and the experience helped spark his motivation to become independent and establish his own translational research lab. Later, as his dream of building a lab began to take shape, Ángel started analysing clinical samples and BBMRI-ERIC played a key role by helping him identify suitable collections for his research and by streamlining access to them. In today’s episode, Angel shares his research, his vision for personalised cancer therapies and offers advice to aspiring scientists considering a career in research.  Further reading:  Lindau Nobel Laureate Meeting: https://www.lindau-nobel.org/ BBMRI Podcast: https://www.bbmri-eric.eu/bbmri-eric/bbmri-eric-podcast/

    21 min
  2. 33 - ELSI Dialogues: Empowering Voices - Enhancing Patient Engagement in Oncology Research

    9 JUL

    33 - ELSI Dialogues: Empowering Voices - Enhancing Patient Engagement in Oncology Research

    “No one has to reinvent the wheel in their work, but we need more visibility for the often invisible work, working with patients and the benefits this has for research.” (Melanie Goisauf) In episode 33 of the BBMRI-ERIC podcast we listen in on a recent BBMRI-ERIC ELSI Dialogues session recorded in June 2025, a vivid experts’ discussion covered concepts and practical means to effectively utilise the potential of patients’ unique perspectives. Moderator Melanie Goisauf, ELSI Senior Scientist at BBMRI-ERIC, discussed ways to successful patient engagement with three invited experts: Margareta Haag (Chair of the Swedish Network against Cancer), Stefanie Houwaart (Patient representative in the German BRCA network) and Zisis Kozlakidis (Head of Laboratory Services and Biobanking at IARC/WHO[ES1] ).   Patient engagement is a continuous process of mutual learningThe challenge of actively involving patients in medical research has many names - patient engagement, participation, involvement or participatory research. The unifying goal behind these terms is to give patients a powerful voice and an active role in the process of developing better and more effective treatments and care for everyone. The discussion revolved around one central question: What does successful patient engagement in research look like? The panellists’ opinions can be summarised as univocal appeal to all involved groups; to keep constantly learning and find solutions together. Researchers need to adapt their work from a patient’s perspective and vice versa - patients benefit from learning the basics of research projects. Stefanie Houwaart (Patient representative in the German BRCA network) emphasised the importance of constant mutual learning: “It's a process. And we are all learning all the time. So, we three [invited experts] might be in the game for several years already. But we are still learning. And lots of people need to learn. And scientists have to be trained in patient engagement. In Germany there is now more and more training for scientists in patient participation, to learn how to do this and implement this in their very own project.” (Stefanie Houwaart) Everyone can become a patient, but it needs time and effort to become a patient representativeMargareta Haag (Chair of the Swedish Network against Cancer) presented her experiences and views from the patient and patient representative perspective. Margareta sketched the journey of a patient who first enters the system without knowing how to navigate it but is able to learn along the way to become an educated patient advocate. “From patient-to-patient advocate, it takes a long time. It's a process. […] It takes time to become a patient that actually can communicate with persons on the other side of the table and then also in research. But you can learn, and you can also teach the professionals that this is the way I work and this is my life.” (Margareta Haag)   From individual efforts to structural changes of the systemBuilding on individual initiatives, the value of bringing educated patient advocates to the table is getting more broadly recognised as an integral part of medical research. But systematically incorporating this into daily research practice needs effort and engagement from all sides to adapt existing systems. Zisis Kozlakidis, virologist and Head of Laboratory Services and Biobanking at IARC/WHO, introduced this aspect addressing structural shortcomings in the system: “Part of successful patient engagement is starting to break down some of the silos that have existed for a long time. One of the issues that we have is that a lot of the systems that we see globally, as part of our work, have not been designed with patient engagement in mind at all. […] Even when there are some initiatives to address this, you still see a space that's filled with professional jargon that is not really addressing the needs of the patient. […]. In this sense, we put a lot of emphasis on the education of the patient, the education of the general public as to what is possible.” (Zisis Kozlakidis)   Practical tips patient involvement in research projectsThe discussion concluded with practical considerations for researchers to help improve future research by involving patients’ advocacy groups. Stefanie Houwaart stressed how important it is to start developing relationships with patient organisations early on: “Often, the reality is that funding organisations, a ministry or the European Commission says, okay, now we have the checkpoint “patients’ participation” and then you have to run and you have to do this in a short time. I would really recommend every scientist who wants to do patient participation, to start reaching out to patient organisations early, even before they have a concrete project in mind.” (Stefanie Houwaart) Melanie Goisauf, Moderator and Senior Scientist at BBMRI-ERIC pointed out the lacking visibility of the progress that is already being made in this field and that researchers and patients can build on: “No one has to reinvent the wheel in their work, but we need more visibility for the often, I would say, invisible work, working with patients and the benefits this has for research.” (Melanie Goisauf)   More BBMRI-ERIC ELSI recordings and eventsStay informed with our ELSI Dialogues and webinars. Upcoming events are advertised on our events page. Including the upcoming 2025 ELSI Symposium in October addressing Ethical, Legal, and Societal Aspects in View of Recent EU Legislation. This podcast is part of the canSERV project, which aims to deliver cutting-edge cancer research services to scientists across EU member states, associated countries, and beyond. The project unites a multidisciplinary consortium of 18 European partners specialising in oncology, project management, and sustainability.   The panellists:Margareta Haag is the Chair of the Swedish Network against Cancer – an umbrella organization for cancer-profiled patient organizations and their families. As a Lymphoma patient since 1994 and Lymphoedema patient since 1995, Margareta acts as a patient representative. Margareta is the Former Executive Director for an international professional body and The Federation of Biomedical Laboratory Science as well as holding various positions including President of the umbrella organization Network against cancer and former President of the Swedish Association of Chronic Oedema. Dr. rer. nat. Stefanie Houwaart MPH has a Diploma in Biology, a Master of Science in Public Health, and Dr. rer. nat. in Pharmaceutical Chemistry. Since 2012, Dr. Houwaart is active member of the patient community and patient representative in science and politics at the BRCA network e.V.. She is also Co-Founder and Managing Director of partieval – Advancing Participatory Skills, Process Support and Evaluation in Health. Dr. Kozlakidis is a virologist, with a PhD in microbiology from Imperial College London. Dr. Kozlakidis is the Head of Laboratory Services and Biobanking at the International Agency for Research on Cancer, World Health Organization (IARC/WHO). Dr. Kozlakidis is responsible for one of the largest and most varied international collections of clinical samples in the world, focusing on gene–environment interactions and disease-based collections. Dr. Melanie Goisauf is an accomplished social scientist with a PhD in Sociology from the University of Vienna. She also studied at the Royal Holloway University of London and completed the postgraduate program "Sociology of Social Practices" at the Institute for Advanced Studies (IHS) Vienna. Dr. Goisauf currently works as senior scientist at BBMRI-ERIC, where she is involved in several research projects and serves on ethical advisory boards. Dr. Goisauf also leads the Ethics of AI Lab, which focuses on the ethical and social implications of artificial intelligence.

    44 min
  3. 32 - Congress Radio: Europe Biobank Week 2025 - Day Four - Ethics Café, a winning pitch and closing thoughts

    17 MAY

    32 - Congress Radio: Europe Biobank Week 2025 - Day Four - Ethics Café, a winning pitch and closing thoughts

    Visit day four of the Europe Biobank Week Congress in this mini-series covering the event - part of the BBMRI-ERIC Podcast.  During these episodes, you’ll experience the congress as it happens in Bologna, Italy from 13-16 May 2025. You’ll get a flavour of the event from interviews with organisers, speakers and delegates. If you missed day three, find it at Europe-biobank-week-dot-eu. EBW is a yearly congress jointly organised between BBMRI-ERIC and ESBB. It unites over 800 biobankers, researchers, industry specialists and decision makers for keynotes, workshops, industry talks and parallel sessions over four days. This final episode, recorded on 16 May, is when congress winds down but the pace is no slower with a vibrant Ethics Café, a set of parallel sessions and the closing ceremony.  Contributors to the episode, as they appear, are: Dr. Jörg Hamann, Amsterdam University Medical CenterDr. Gesine Richter, University KielProf. Prof. Roland Jahns, Universitätsklinikum WürzburgProf. Ali Kilic, Izmir Biomedicine And Genome CenterMariona Arañó Loyo, Fundació Sant Joan de DéuDr. Maria Grazia Cerrito, University of Milano BicoccaDr. Mindaugas Morkunas, Vilnius University Hospital Santaros KlinikosElsa Roland, Oslo University HospitalPatrick Skowronek, German Cancer Research Center (dkfz) Links: Sant Joan de Déu: https://www.sjdhospitalbarcelona.org/enClosing ceremony award recipients: https://www.europebiobankweek.eu/ebw-news/ebw25-live/ebw25-live-closing-ceremony/Europe Biobank Week: https://www.europebiobankweek.euBBMRI-ERIC: https://www.bbmri-eric.euESBB: https://esbb.org

    28 min
  4. 31 - Congress Radio: Europe Biobank Week 2025 - Day Three - Participants, Posters and EP PerMed

    15 MAY

    31 - Congress Radio: Europe Biobank Week 2025 - Day Three - Participants, Posters and EP PerMed

    Visit day three of the Europe Biobank Week Congress in this mini-series covering the event - part of the BBMRI-ERIC Podcast.  Europe Biobank Week Congress is happening in Bologna, Italy from 13-16 May 2025. You’ll hear a flavour of the event through interviews with organisers, speakers and delegates. If you missed day one, find it at the Europe Biobank Week website. EBW is the most important event of the year for the global biobanking community. A yearly congress, jointly organised between BBMRI-ERIC and ESBB, it unites over 800 biobankers, researchers, industry specialists and decision makers from across the life sciences to discuss the latest innovative research and industry changes. It features keynotes, parallel sessions and workshops and is held over four days. This episode, recorded on 15 May, is when congress is in full swing. Contributors to the episode, as they appear, are: Istahil Mohammed Ibrahim, Statens Serum InstitutAdrie Kromhout, Amsterdam University Medical CenterProf. Professor Mait Metspalu, Institute of Genomics, University of TartuDonal Melanaphy, Thermo Fisher ScientificTania Porqueddu, Università Di SassariDr. Gianni D’Errico, Toscana Life Sciences Dr. Piotr Mrówka, Institute of Hematology and Transfusion MedicineDr. Mignon van Gent, Amsterdam University Medical Centre Links: Estonian Biobank: https://genomics.ut.ee/en/content/estonian-biobankEP PerMed: https://www.eppermed.eu/Europe Biobank Week: https://www.europebiobankweek.euBBMRI-ERIC: https://www.bbmri-eric.euESBB: https://esbb.org

    21 min
  5. 30 - Congress Radio: Europe Biobank Week 2025 - Day Two - Scientific Programme Launch

    14 MAY

    30 - Congress Radio: Europe Biobank Week 2025 - Day Two - Scientific Programme Launch

    Visit day two of the Europe Biobank Week Congress in this mini-series covering the event - part of the BBMRI-ERIC Podcast.  Europe Biobank Week Congress is happening in Bologna, Italy from 13-16 May 2025. You’ll hear a flavour of the event through interviews with organisers, speakers and delegates. If you missed day one, find it at the Europe Biobank Week website. EBW is the most important event of the year for the global biobanking community. A yearly congress, jointly organised between BBMRI-ERIC and ESBB, it unites over 800 biobankers, researchers, industry specialists and decision makers from across the life sciences to discuss the latest innovative research and industry changes. It features keynotes, parallel sessions and workshops and is held over four days. This episode, recorded on 14 May, is when congress kicked off the scientific programme and covers the highlights. Contributors to the episode, as they appear, are: Prof. Antonio Zoccoli, President of the ICSCProf. Walter Ricciardi, Università Cattolica del Sacro Cuore, RomeDr. Nicola Miller, School of Medicine, University of GalwayZohaib Hassan, German Biobank NodeProf. Elke Smits, Antwerp University Hospital and ESBB AmbassadorDr. Ricard Martinez, University of ValenciaDipl.-Ing. Roland Leiminger, ESBBProf. Jens K Habermann, BBMRI-ERIC Links: Europe Biobank Week: https://www.europebiobankweek.euBBMRI-ERIC: https://www.bbmri-eric.euESBB: https://esbb.orgICSC: https://www.supercomputing-icsc.it/en/

    14 min
  6. 29 - Congress Radio: Europe Biobank Week 2025 - Day One - Workshops

    13 MAY

    29 - Congress Radio: Europe Biobank Week 2025 - Day One - Workshops

    Visit day one of the Europe Biobank Week Congress in this mini-series covering the event - part of the BBMRI-ERIC Podcast.  Europe Biobank Week Congress is happening in Bologna, Italy from 13-16 May 2025. You’ll hear a flavour of the event through interviews with organisers, speakers and delegates.  EBW is the most important event of the year for the global biobanking community. A yearly congress, jointly organised between BBMRI-ERIC and ESBB, it unites over 700 biobankers, researchers, industry specialists and decision makers from across the life sciences to discuss the latest innovative research and industry changes. It features keynotes, parallel sessions and workshops and is held over four days. This episode takes you to the first day - 13 May - which hosts several workshops run by experts within their field. Learn what makes the workshops unique and how they’re valued as education opportunities by delegates. Contributors to the episode, as they appear, are: Prof. Antonino Rotolo, Università di BolognaDr. Nabila Choudhry - Research Analyst-Ethicist at WCM-QHugas Jasinskas, IT Specialist from The Biobank of Lithuanian Population and Rare DisordersProf. Marialuisa Lavitrano, National Node Director for BBMRI ItalyDr. Sissy Kolyva, Hellenic Pasteur Institute AthensStella Antoniou, Quality Manager at. BMRI-ERICDr. Marta Sobalska-Kwapis, Centre for Digital Biology and Biomedical Science - Biobank Lodz Links: Europe Biobank Week: https://www.europebiobankweek.euBBMRI-ERIC: https://www.bbmri-eric.euESBB: https://esbb.org

    15 min
  7. 28 - ELSI Dialogues: Navigating the Future: Legal and IT Challenges, Risks, and Opportunities of AI in Biobanking

    8 MAY

    28 - ELSI Dialogues: Navigating the Future: Legal and IT Challenges, Risks, and Opportunities of AI in Biobanking

    “The technology is there. What is not there immediately, is how to use the technology properly.”(Prof. Marco Montali) In episode 28 of the BBMRI-ERIC podcast, Ilaria Colussi, Data Protection Officer at BBMRI-ERIC, and two guest experts discuss legal and technical aspects of using AI tools for biobanking. How can AI help modern biobanking? How can biobanks with their vast data and sample collections support the development of AI tools for e.g., medical diagnostics? And what are the legal frameworks that regulate the use and development of this rather young technology with its huge impact on humankind? The EU AI act as pioneering attempt to legislate AI applications New applications for AI tools/algorithms are currently blooming like spring flowers and it can be overwhelming to decide which of them can be integrated in one’s daily routine safely and responsibly. This holds true for personal use but especially for biobanking where large collections of sensitive biological samples and data are stored and made accessible for research. Prof. Nikolaus Forgó (University of Vienna) is Professor for IT and IP law and a leading advisor e.g., as an expert member of the Austrian Data Protection Council and Member of the AI Advisory Board. In the first part of this episode, Prof. Forgó summarises the current state of the developing AI legislation in Europe: “The pieces of legislation coming, in principle apply to everything. Be it Meta, be it a biobank, be it a public government institution. And two pieces of this legislation are of specific relevance for biobanks: The EU AI act and the EHDS (European Health Data Space) Act.”(Prof. Nikolaus Forgó) The EU AI act is globally the pioneering first legislation for a responsible use of AI. The challenge is to navigate how we can leverage the potential of AI applications in a responsible manner while securing privacy and safety rights of citizens and patients. Prof. Forgó describes the approach of the EU legislation to broadly assess the risks of AI applications: “The AI act is the attempt of the European legislator to control the risks coming with AI. So, it's mainly about assessment of risks and then introducing specific obligations for specific risk categories.”(Prof. Nikolaus Forgó) A technical view on implementing AI applications into biobanking The second guest expert speaker, Prof. Marco Montali (Free University of Bozen-Bolzano, Italy), is an expert in Computer Engineering and was awarded by the Italian Association of Artificial Intelligence the best under 35 Italian researcher in Artificial Intelligence. In the second part of this episode, Prof. Montali discusses technical aspects and consideration that are relevant when AI tools are introduced into biobanking. Prof. Montali points out the current challenges of AI integration: “The technology is there. What is not there immediately, is how to use the technology properly.”(Prof. Marco Montali) Biobanks are in a position where they can hugely benefit from algorithms that are able to process and analyse large amounts of data. Vice versa, biobanks can provide such large amounts of high-quality data including medical images, that are essential to develop and train these specialised AI tools in the first place. Prof. Marco Montali describes this reciprocal benefit for AI research and biobanking with an example: “It's not only biobanking helping AI, but AI helping biobanking, even before thinking about which problem we want to solve with AI. […] A lot of AI research is being focused on being able to integrate, to reconcile, to prepare, to clean the data. Obviously, this is connected to data science as a whole for then fuelling other AI algorithms.”(Prof. Marco Montali) When humans and AI work together A critical aspect that touches all points of this discussion is the question how we can optimally utilise human-AI interactions for the best possible outcome. Where is it essential to include human oversight? How can medical experts integrate AI support in their work to improve and accelerate diagnosis? We need to understand and decide which tasks can be performed faster and maybe more reliably by an AI algorithm and which tasks strongly rely on the unique expertise of a trained medical expert. This is a challenge but also a huge opportunity for biobanking and biobank-related medical research and diagnostics.   Further reading:The EU AI actThe European Health Data Space (EHDS)

    50 min
  8. 27 - ELSI Dialogues: The Nagoya Protocol applied to Biobanks

    13 MAR

    27 - ELSI Dialogues: The Nagoya Protocol applied to Biobanks

    “It’s not a secret to anybody that the biodiversity is decreasing on all continents, and this implies a lot of important issues for the day-to-day life of human beings. For a sustainable use of the biodiversity and benefit sharing, the Nagoya protocol was adopted.”(Melania Muñoz Garcia) Sharing is caring. This also holds true for biological samples and data as resources for research. Episode 27 of the BBMRI-ERIC podcast explores how the Nagoya Protocol - an international agreement regulating collection, storage and sharing of non-human genetic resources - helps biobankers and researchers to distribute and utilise these resources responsibly, especially in times of globally decreasing biodiversity. A key aspect of the agreement is the goal to share any benefits that arise from utilisation of these resources in a fair and equitable way between the country/institution that stores and provides the resources and those who use it. This promotes responsible use and fosters collaborations. “Compliance with the Nagoya Protocol is not just a legal requirement, it's a powerful tool for promoting fair and equitable sharing of genetic resources.”(Christian de Guttry). In this recording of our latest ELSI Dialogues session in February 2025, three invited expert speakers joined host Ilaria Colussi, BBMRI-ERIC’s Data Protection Specialist, to share their knowledge and practical experience with the Nagoya protocol. Melania Muñoz Garcia (Leibniz Institute, DSMZ), Josephine Uldry (Swiss Biobanking Platform) and Christian de Guttry (Swiss Institute of Bioinformatics) describe the fundamental basics of the Nagoya Protocol and explore practical examples how the Nagoya protocol is applied in different countries and institutions. Changes in daily practise have to go hand in hand with a change of the perception among researchers that compliance to regulations is a bureaucratic burden. In contrast, following the Nagoya Protocol’s guidelines supports ethical and reproducible science with genetic resources, with biobanks as crucial players. You can also watch this and previous ELSI Dialogues sessions as webinar video recordings on our Youtube channel.   Further reading: The Nagoya protocol: https://www.cbd.int/abs/default.shtmlThe Nagoya protocol at the Leibniz Institute DMSZ website: https://www.dsmz.de/collection/nagoya-protocolSharing nature’s genetic resources by the EC: https://environment.ec.europa.eu/topics/nature-and-biodiversity/sharing-natures-genetic-resources_enELSI Dialogues on Youtube: https://www.youtube.com/watch?v=aZA1rVT75toELSI services: https://www.bbmri-eric.eu/elsi/

    43 min

Ratings & Reviews

5
out of 5
2 Ratings

About

A podcast that tells the latest success stories and innovations from across the European biobanking and biomolecular resources landscape.